Kornimate/medical-research-clean huggingface dataset:
pilot the use of va make the connection campaign to facilitate help seeking among vulnerable veterans

Conditions: Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse); Help-Seeking Behavior

Summary: this pilot study seeks to determine if exposure to the make the connection campaign messages developed by the u.s. department of veterans affairs (va) is associated with changes in mental-health related outcomes, specifically: (1) psychosocial determinants that drive help seeking behaviors (knowledge, attitudes and intentions); and (2) perceived barriers to seeking care. participants are randomly assigned to message exposure or control (no exposure) conditions. data from this project will inform mental health education and outreach efforts targeted towards veterans experiencing mental health concerns.


Eligibility criteria:
inclusion criteria: veterans of all gender/sex, race/ethnicities that in the past 6 months: * utilized health services in the u.s. department of veterans affairs (va); * screened positive on the phq-2, audit-c or pc-ptsd and/or received a mental health diagnosis as documented in va medical record * fluent in english language * capable of understanding goals of study * capable of providing verbal consent * willing and able to download/use study android mobile application for duration of study exclusion criteria: * not a u.s. veteran who has utilized va health care in the past 6 months * did not screen positive and/or was not diagnosed with mental health disorder * determined cognitively impaired and unable to provide verbal consent * determined to be in high distress during recruitment screening * currently institutionalized (i.e., hospitalized; incarcerated, etc.) * unwilling and/or unable to download and use use the study app

Keywords: mental health promotion campaign veterans
ultrasound perfusion estimation for assessment of peripheral arterial disease

Conditions: Peripheral Arterial Disease

Summary: the purpose of this study is to develop a new noninvasive tool for early diagnosis of peripheral arterial disease (pad) and use the proposed method for monitoring the disease progression and the response to interventional treatment in pad patients.


Eligibility criteria:
inclusion criteria: patient volunteers: * male and female, ages 18 years old and up * symptom of claudication and suspected for pad * scheduled for vascular testing. healthy volunteers: * male and female, ages 18-75 years old and up * normal bmi * no history of smoking, cardiovascular disease, or diabetes. exclusion criteria: patient volunteers: * patients with gangrene * patients having surgery or stent * patients with ulcer on their leg * any health condition that does not allow proper use of ultrasound scanning * people considered in "vulnerable" populations. healthy volunteers: * include volunteers with bmi not more than 30 * no history of smoking * no history of (diabetes, hypertension, cardiovascular diseases) * people considered in "vulnerable" populations.
zevalin plus bucye high-dose therapy in b-cell non-hodgkin's lymphoma

Conditions: Non-Hodgkin's Lymphoma

Summary: in order to improve the clinical result of high-dose chemotherapy and autologous stem cell transplantation for b-cell non-hodgkin's lymphoma, zevalin will be added to the conditioning regimen. investigators expect this radioimmunotherapy of zevalin plus busulfan, cyclophosphamide and etoposide regimen will improve survival of relapsed or poor-risk b-cell non-hodgkin's lymphoma.

title: combining 90y-ibritumomab tiuxetan (zevalin) with high-dose chemotherapy of bucye and autologous stem cell transplantation in patients with relapsed, refractory, or high-risk b-cell non-hodgkin's lymphoma - an open-labeled phase ii study. study design: prospective, multicenter, open-labeled, phase ii trial. study objectives: * primary: event-free survival time following autologous stem cell transplantation with 90y-ibritumomab tiuxetan and bucye high-dose chemotherapy in patients with relapsed, refractory, or high-risk b-cell non-hodgkin's lymphoma * secondary: overall survival response rate toxicity of the treatment combination treatment: z-bucye regimen * day 21: rituximab, 250 mg/m2, i.v. * day 14: rituximab, 250 mg/m2, i.v. 90y-ibritumomab tiuxetan, 0.4 mci/kg, i.v. * day 7, 6, 5: busulfan 3.2 mg/kg i.v. * day 5, 4: etoposide 200 mg/m2 i.v. every 12 hours * day 3, 2: cytoxan 50 mg/kg i.v. * day 0: autologous stem cell infusion

Eligibility criteria:
inclusion criteria: * histologically confirmed b-cell nhl in chemotherapy-sensitive relapse, in partial response to 1st line chemotherapy, or in complete response after 1st line chemotherapy with high ipi score at diagnosis * age \< 65 years old * who performance status (ps) of 0-2 * anc \> 1,500/mm3, platelet \> 100,000/mm3 * cr \ 50 ml/min * transaminase \< 3x upper normal value * bilirubin \< 2 mg/dl * life expectancy of at least 3 months * written informed consent * optimal harvest of autologous stem cells (cd34+ cells \> 5 million/kg plus 2 million/kg for back-up) exclusion criteria: * prior hematopoietic stem cell transplantation * prior rit * prior external radiation to \> 25% of active bone marrow * cns involvement of non-hodgkin's lymphoma * serious comorbid diseases * hiv or htlv-1 associated malignancy * history of other malignant disease in the previous 5 years, except squamous cell or basal cell carcinoma of skin or stage i uterine cervical carcinoma or cervical carcinoma in situ * known hypersensitivity to murine antibodies/proteins * pregnant or breast feeding female patients, adults without effective contraception up to 12 months after rit * persistent toxic side effects from prior therapy * prior biologic or immunotherapy less than 4 weeks prior to entry on this study * investigational drugs less than 4 weeks prior to entry on this study

Keywords: zevalin b-cell non-hodgkin's lymphoma autologous stem cell transplantation bucye regimen
reliability and validity of the vicorder device when measuring pulse wave velocity within chronic stroke patients

Conditions: Stroke

Summary: stroke is a major global health problem and main cause of disability worldwide. blood pressure control is important for good health in stroke patients. measuring central blood pressure (the blood pressure which is found in the heart) and measuring the stiffness of your arteries will give practitioners, clinicians and researcher's important information over and above what is usually obtained from peripheral blood pressure in the arm. the most validated and most recognisable equipment for central blood pressure and arterial stiffness is the sphygmocor xcel. however, the doppler ultrasound is used more often in population-based studies and has been shown to be a precise and accurate measurement. although these devices are validated, they both require a highly skilled operator and are quite time-consuming. as such, it is important to explore less operator dependent and time consuming devices, such as the vicorder, as this could be essential for researchers and clinicians.therefore, this study will investigate whether the vicorder device is valid and reliable when measuring these outcomes and if so could be implemented in large research studies and potenially be used by clinicians.

twenty stroke patients will be recruited for this study. participants will take part in four seperate assessments (2 hours each) with a minimum of 24 hour recovery between each session. before each assessment participants will undertake an overnight fast (only water is allowed to be consumed prior to the assessment). if required, participants will take their medication the morning of each assessment and this will be noted.during the first session participants will be randomised into either a supine or seated condition. participants will rest in this posture for 15 minutes. triplicate measures of peripheral blood pressure and pulse wave analysis will be measured using the sphygmocor xcel and vicorder device. a 3-lead ecg will be placed on the participant and ultrasound measures will be taken at the carotid, brachial, femoral and posterior tibial artery. this will examine the caroid-femoral pulse wave velocity (cfpwv), brachial-femoral pulse wave velocity (bfpwv), brachial-ankle pulse wave velocity (bapwv) and femoral-ankle pulse wave velocity (fapwv). following this, the vicorder device will be used to measure these segments. all measures will be on both symptomatic and asymptomatic sides. this procedure will be repeated in a seperate session whereby individuals will be in the other posture. session 3 and 4 will include participants resting for 15 minutes in a supine position. triplicate measures of peripheral blood pressure and pulse wave analysis will be taken with the vicorder. followed by triplicate measures of cfpwv, bfpwv, bapwv and fapwv. this will be repeated in a seated position within the same session.

Eligibility criteria:
inclusion criteria: * diagnosis of stroke by a stroke cnsultant from a uk national health service foundation trust * 3 months to 5 years of study start date
hospital acquired and community acquired mrsa in gi lab

Conditions: Hospital Acquired MRSA; Community Acquired MRSA

Summary: hospital acquired and community acquired methicillin resistant staph aureus (mrsa) has become an important health issue for in recent years. up to two thirds of patients that are hospitalized may be colonized with mrsa. the prevalence in the community is also on the rise and affects the young and healthy. it is unclear what the true prevalence of mrsa is in our own hospital and outpatient setting. this information would be relevant to how healthcare staff adhere to contact and universal precautions. : the purpose of this study is to determine the prevalence of mrsa in patients that have gastrointestinal endoscopy and endoscopic ultrasound.


Eligibility criteria:
inclusion criteria: * no evidence of dementia or altered mental status that would prohibit the giving and understanding of informed consent, and no evidence of psychiatric risk that would preclude adequate compliance with this protocol. subjects must provide signed written informed consent. exclusion criteria: * inability to provide written informed consent.
ibrutinib and acalabrutinib use and risk of atrial fibrillation in patients with chronic b-cell malignancies

Conditions: Chronic B-cell Malignancies; BTK Inhibitors; Cardiovascular Diseases

Summary: background. ibrutinib and acalabrutinib are both associated with an increased risk of atrial fibrillation (af) but af comparative risk between these 2 btk inhibitors (btkis) remains largely unknown. objectives. our aim was to examine the risk of developing incident af with ibrutinib exposure compared with acalabrutinib exposure. methods. using the trinetx research network database, authors will conduct a retrospective cohort analysis of deidentified, aggregate adult patients with chronic b-cell malignancies and exposed to ibrutinib or acalabrutinib. patients will be divided into 2 groups based on ibrutinib or acalabrutinib exposure. after propensity score matching (psm), hazard ratios (hrs) and their associated 95% confidence intervals (cis) will be used to compare af risk during follow-up between the matched 2 groups.


Eligibility criteria:
inclusion criteria: * adult patients * diagnose with chronic b-cell malignancies using icd-10-cm codes c91 (lymphoid leukemia), c88.0 (waldenström macroglobulinemia), c83.1 (mantle cell lymphoma), c81-c96 (malignant neoplasms of lymphoid, hematopoietic and related tissue) or c95 (leukemia of unspecified cell type) * expose to ibrutinib or acalabrutinib determined by the anatomical therapeutic chemical codes exclusion criteria: -
study to evaluate the efficacy and safety of pt20 in subjects with hyperphosphataemia and dialysis dependent chronic kidney disease

Conditions: Hyperphosphataemia

Summary: the main purpose of this study is to see whether pt20 can help people with a high level of phosphate in their blood (called hyperphosphatemia) that are being treated with dialysis for kidney disease.

pt20 represents a mechanism to address many of the limitations associated with current phosphate binding agents. the available clinical and non clinical evidence suggests that pt20 binds phosphate and prevents its uptake more efficiently than other phosphate binding drugs and may therefore either reduce the pill burden associated with controlling phosphate levels, or result in lower phosphate levels with the same pill burden. the this study is the first to investigate the efficacy and safety of pt20 in subjects with dialysis-dependent chronic kidney disease (ckd).

Eligibility criteria:
inclusion criteria: * men or women aged 18 90 years * subject must have a stable dialysis prescription for at least 28 days prior to start of screening. * subject must have the most recent serum phosphate measurement, taken during the 28 days prior to the start of screening, of ≥ 4.0 mg/dl and ≤ 8 mg/dl. exclusion criteria: * subject's most recent historical pre-dialysis serum bicarbonate value within 14 days prior to the start of screening (visit 1) is \< 18 mg/dl. * subject has, in the opinion of the investigator, severe chronic lung disease and/or carbon dioxide retention.

Keywords: dialysis dependent chronic kidney disease
symptoms and management strategies in gastroesophageal reflux disease (gerd)

Conditions: Gastroesophageal Reflux Disease

Summary: this a non-interventional multi-centre study to evaluate the symptom load and management strategies in ppi-treated gerd patients with persistent gerd symptoms..


Eligibility criteria:
inclusion criteria: * provision of informed consent * subjects with a diagnosis of gerd and with predominant typical gerd symptoms: heartburn/regurgitation * subjects who fail to obtain satisfactory symptomatic response after their first full course (4-8 weeks) of standard dose ppi (once a day) exclusion criteria: * inability to read and/or understand patient reported outcomes questionnaires * subjects where the only reason for the visit is renewing the prescription * a history of an incomplete response to ppi treatment prior to current course of treatment

Keywords: gerd ppi
a study to evaluate the safety, tolerability, kinetics and repeatability of 18f-bms-986327

Conditions: Healthy Participants; Idiopathic Pulmonary Fibrosis (IPF)

Summary: the purpose of this study is to assess the safety, tolerability, kinetics and test-retest repeatability of the novel lpa1 positron emission tomography (pet) ligand 18f-bms-986327 in healthy participants and participants with idiopathic pulmonary fibrosis (ipf).


Eligibility criteria:
inclusion criteria: all participants: · body mass index of 18.0 to 34.0 kg/m\^2, inclusive, and body weight ≥ 50 kg healthy participants: * male and female healthy volunteers ages 18 or age or older * no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ecgs) and clinical laboratory determinations idiopathic pulmonary fibrosis (ipf) participants: * male and female participants aged 40 to 90 years * diagnosis of ipf less than 6 years before randomization * have no features supporting an alternative diagnosis on transbronchial biopsy, bronchoalveolar lavage or surgical lung biopsy exclusion criteria (all participants): * severe motor problems that prevent the ability to lie still for pet imaging procedure * significant acute or chronic medical illness in the opinion of the investigator in consultation with the bms medical monitor, could jeopardize the subject's safety, tolerability, or pharmacokinetics of 18f-bms-986327 * current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug * any major surgery within 4 weeks of study drug administration other protocol-defined criteria apply

Keywords: healthy participants idiopathic pulmonary fibrosis (ipf)
the effect of broken ganoderma lucidum spore powder on quality of life and immune function in patients with diffuse large b-cell lymphoma after chemotherapy

Conditions: Diffuse Large B-cell Lymphoma

Summary: the purpose of this study was to explore the effect of broken ganoderma lucidum spore powder on improving the quality of life and immune recovery of patients after chemotherapy. objective to observe the adjuvant treatment with broken wall ganoderma lucidum spore powder in patients with diffuse large b-cell lymphoma after standard chemotherapy according to nccn guidelines. to evaluate and compare the immunoglobulin (iga, igm, igg), t cell subsets (cd3 +, cd4 +, cd8 +, cd4 + / cd8 +), th1 / th2 cytokine determination, quality of life score, leukocyte recovery rate, infection rate, infection rate to evaluate the effect of ganoderma lucidum spore powder in improving the quality of life and immune function of patients after chemotherapy. at the same time, the liver and kidney function and adverse drug events were closely monitored during the study to explore the clinical safety of wall broken ganoderma lucidum spore powder as adjuvant drug.


Eligibility criteria:
inclusion criteria: * diffuse large b-cell lymphoma，nos * all patients were diagnosed for the first time * between 18-75 years old, male and female * ecog 0-3 ，the expected survival was more than 6 months * the pregnancy test of women of childbearing age was negative; male and female patients should agree to take effective contraceptive measures during the treatment period and one year of follow-up; * sign the informed consent before the test screening exclusion criteria: * those who are known to be allergic to the study drug or its related components; or allergic patients * uncontrolled psychosis * participating in other trials at the same time, and using experimental drugs that may affect the efficacy and safety evaluation * impairment of liver and kidney function * hiv antibody positive; * hbsag positive hepatitis b carriers and confirmed hepatitis b and c patients; * pregnant or lactating women and patients who do not agree to take effective contraceptive measures; * the patient is unable to swallow the capsule or has a disease or condition that seriously affects the gastrointestinal function;

Keywords: broken ganoderma lucidum spore powder
prospective trial for endoscopic ultrasound guided gallbladder drainage for acute cholecystitis in high risk patients

Conditions: Cholecystitis

Summary: the investigators would like to conduct a prospective, randomized non-inferiority study to compare clinical outcome between endoscopic ultrasound (eus) guided gallbladder drainage and percutaneous transhepatic gallbladder drainage (ptgbd) in high risk acute cholecystitis patients.

the primary outcome is to compare clinical resolution rate of eus-guided gallbladder drainage versus percutaneous transhepatic gallbladder drainage in acute cholecystitis patients with high risk. the secondary outcome is to compare complications, conversion rate to open cholecystectomy during laparoscopic cholecystectomy.

Eligibility criteria:
inclusion criteria: * high risk for general anesthesia and emergency operation (american society of anesthesiologists, asa grade iii or iv) exclusion criteria: * age below 18 years * pregnancy * when the risks of endoscopy to patient are judged to outweigh the most favorable benefits of the procedure. * unstable or unwilling to comply with follow-up * when a perforated viscus is known or suspected * simultaneously participating in another investigational drug or device study

Keywords: eus-guided transmural cholecystostomy
topotecan and thalidomide in treating patients with recurrent or refractory malignant glioma

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. thalidomide may stop the growth of cancer by stopping blood flow to the tumor. purpose: phase i trial to study the effectiveness of combining topotecan and thalidomide in treating patients who have recurrent or refractory malignant glioma.

objectives: * determine tumor response rate, duration of response, time to disease progression, and overall survival of patients with recurrent or refractory malignant glioma treated with topotecan and thalidomide. * determine safety and tolerance of this regimen in these patients. outline: patients receive topotecan iv continuously on days 1-21 and oral thalidomide daily on days 1-28. treatment repeats every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. patients are followed every 2 months. projected accrual: approximately 20 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologically confirmed recurrent or progressive supratentorial glioblastoma or anaplastic astrocytoma * measurable disease by mri or ct scan * no gliomatosis cerebri, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma * concurrent registration for the system for thalidomide education and prescribing safety (s.t.e.p.s.) program patient characteristics: age: * over 18 performance status: * ecog 0-2 life expectancy: * not specified hematopoietic: * wbc greater than 4,000/mm\^3 * platelet count greater than 100,000/mm\^3 hepatic: * bilirubin less than 2.0 mg/dl renal: * creatinine less than 1.6 mg/dl other: * no other concurrent malignancy except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix * not pregnant or nursing * negative pregnancy test * fertile patients must use 2 methods of effective contraception 1 month prior to, during, and for 1 month after study participation prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no more than 2 prior chemotherapy regimens in adjuvant or metastatic setting * at least 4 weeks since prior chemotherapy endocrine therapy: * not specified radiotherapy: * not specified surgery: * not specified other: * concurrent anticonvulsants allowed

Keywords: recurrent adult brain tumor adult glioblastoma adult anaplastic astrocytoma adult giant cell glioblastoma adult gliosarcoma
measurement of joint attention fluency

Conditions: Autism Spectrum Disorders; Autism

Summary: the purpose of this research is to study joint attention. joint attention plays a critical role in social and language development in children with and without autism. joint attention is the shared attention between a child and another person. this study seeks to set a standard benchmark of frequency scores for joint attention. finding a rate of engaging in joint attention behavior would offer a benchmark for all researchers and practitioners working with learners with and without autism.


Eligibility criteria:
inclusion criteria: * autism spectrum disorder exclusion criteria: * hearing or vision problems * behaviors that are a danger to self or others

Keywords: autism spectrum disorders autism joint attention imitation fluency